Precise execution

MC Services is...

Client News



… an international Corporate Communications and Investor Relations firm providing high-level consultancy with targeted services and support for transaction-oriented assignments throughout Europe and the United States.


read more


MC Services one of the main sponsors of the 9th DVFA Life Science Conference 2016

MC Services will once again be one of the main sponsors of the 9th DVFA Life Science Conference, which takes place in Frankfurt on June 14, 2016. Over recent years the DVFA Life Science Conference has become a highly valued platform to discuss new innovative technologies, therapies and products with financial market participants.

This year’s conference titled "Next Level Targeted Therapies – Game Changing Technologies for Future Medicine" focuses on innovative treatment strategies and new therapies that have the potential to significantly change the treatment environment. Such a shift in cancer treatment includes immuno-oncology therapies, directing the immune system to eliminate tumor cells, libraries of highly specific and efficient antibodies against a broad portfolio of targets and personalized T-cell immunotherapies that are just some of the key developments in this field. MC Services’ clients have taken leading roles in the development of innovative approaches and exploring new ways of fighting cancer with the potential to transform current treatment approaches.


read more


MC Services sponsors Best Technology Award at the 2016 European Mediscience Awards

MC Services proudly contributed to this year’s European Mediscience Awards as sponsor of the Best Technology Award, for innovative technology that is well funded and capable of significant commercial success.


Mediscience Awards 2016: The winners have been crowned

It is done: after much anticipation the winners of the 2016 Mediscience Awards have been crowned! A huge congratulation to all the winners & shortlisted companies!

read more


Please also follow us on Twitter (@MCServicesAG)

RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D


VAXIMM Elects New Members to Board of Directors


Two Recent Publications on Pritelivir Confirm the Potency of the Novel AiCuris Anti-Herpes Simplex Virus Drug


U.S. FDA grants Priority Review for Nicox’s AC-170 New Drug Application


Kiadis Pharma Appoints PCT as its Contract Manufacturing Organization in the United States


TxCell exercises option from Weizmann Institute of Science following effective grant of broad CAR-Treg patent in Europe


SYGNIS AG announces outcome of Annual General Meeting 2016 


PAION reports positive remimazolam headline data in pivotal U.S. Phase III study in procedural sedation for colonoscopy


Proposed Placing to raise c. £44.7 million (US$63.3 million) and Notice of General Meeting


TxCell implements a new financing contract of up to €20 million in nominal value through convertible notes with warrants (OCABSA)


Analysis of ongoing ABX203 Phase IIb/III trial in chronic hepatitis B virus infection shows good safety, but primary endpoint of study is unlikely to be reached


SYGNIS AG announces new tool for the detection and amplification of cell- free DNA in blood, a critical step for the early diagnosis and prevention of tumors